atogepant - Profile

What are the generic drug sources for atogepant and what is the scope of freedom to operate?

Atogepant is the generic ingredient in one branded drug marketed by Abbvie and is included in one NDA. There are eight patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Atogepant has one hundred and forty patent family members in forty-seven countries.

Summary for atogepant

International Patents:	140
US Patents:	8
Tradenames:	1
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for atogepant

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for atogepant

Constraining patent/regulatory exclusivity:

10,117,836

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Paragraph IV (Patent) Challenges for ATOGEPANT

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
QULIPTA	Tablets	atogepant	10 mg, 30 mg and 60 mg	215206	6	2025-09-29

US Patents and Regulatory Information for atogepant

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	QULIPTA	atogepant	TABLET;ORAL	215206-001	Sep 28, 2021		RX	Yes	No	12,090,148
Abbvie	QULIPTA	atogepant	TABLET;ORAL	215206-001	Sep 28, 2021		RX	Yes	No	12,350,259
Abbvie	QULIPTA	atogepant	TABLET;ORAL	215206-001	Sep 28, 2021		RX	Yes	No	12,383,545
Abbvie	QULIPTA	atogepant	TABLET;ORAL	215206-001	Sep 28, 2021		RX	Yes	No	12,465,598
Abbvie	QULIPTA	atogepant	TABLET;ORAL	215206-001	Sep 28, 2021		RX	Yes	No	9,499,545		Y	Y
Abbvie	QULIPTA	atogepant	TABLET;ORAL	215206-001	Sep 28, 2021		RX	Yes	No	8,754,096		Y	Y

EU/EMA Drug Approvals for atogepant

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
AbbVie Deutschland GmbH & Co. KG	Aquipta	atogepant	EMEA/H/C/005871Aquipta is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month	Authorised	no	no	no	2023-08-11

International Patents for atogepant

Country	Patent Number	Title	Estimated Expiration
European Patent Office	2638042	DÉRIVÉS DE PIPÉRIDINONE CARBOXAMIDE AZAINDANE EN TANT QU'ANTAGONISTES DU RÉCEPTEUR CGRP (PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS)
Poland	2638042
Spain	2525021
Australia	2019283670
Hong Kong	1183862	哌啶羧基酰胺阿酰啶 降鈣素基因相關肽 受體拮抗劑 (PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS (AZAINDANE)(CGRP))
Australia	2021409718

Supplementary Protection Certificates for atogepant

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2638042	122023000058	Germany		PRODUCT NAME: ATOGEPANT ODER PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/23/1750 20230811
2638042	LUC00321	Luxembourg		PRODUCT NAME: ATOGEPANT OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; AUTHORISATION NUMBER AND DATE: EU/1/23/1750 20230814
2638042	202340027	Slovenia		PRODUCT NAME: ATOGEPANT OR ITS PHARMACEUTICALLY ACCEPTABLE SALT; NATIONAL AUTHORISATION NUMBER: EU/1/23/1750; DATE OF NATIONAL AUTHORISATION: 20230811; AUTHORITY FOR NATIONAL AUTHORISATION: EU
2638042	23C1039	France		PRODUCT NAME: ATOGEPANT DANS TOUTES LES FORMES PROTEGEES PAR LE BREVET DE BASE; REGISTRATION NO/DATE: EU/1/23/1750 20230814
2638042	C20230034	Finland
2638042	C202330039	Spain		PRODUCT NAME: ATOGEPANT O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO; NATIONAL AUTHORISATION NUMBER: EU/1/23/1750; DATE OF AUTHORISATION: 20230811; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/23/1750; DATE OF FIRST AUTHORISATION IN EEA: 20230811

Atogepant: Market Dynamics, Investment Scenario, and Financial Trajectory Analysis

Last updated: February 3, 2026

---

Executive Summary

Atogepant, a calcitonin gene-related peptide (CGRP) receptor antagonist developed by AbbVie, targets episodic migraine prevention. Since its FDA approval in September 2021, it has gained prominence in a competitive landscape comprising various CGRP inhibitors. This report assesses atogepant's investment potential by examining market needs, competitive positioning, regulatory environment, sales forecasts, and potential risks.

---

1. Overview of Atogepant

Attribute	Details
Developer	AbbVie
Indication	Preventive treatment of episodic migraine in adult patients
Approval Date	September 2021 (FDA)
Formulation	Oral, once-daily tablet (60 mg)
Market Position	First oral CGRP receptor antagonist for migraine prevention

---

2. Market Dynamics

2.1. Epidemiology and Market Demand

Parameter	Data	Source
Global migraine prevalence	~1 billion (approx. 14%) of the global population	WHO [1]
Adults with episodic migraine	Approximately 50–60% of migraine sufferers	IHS [2]
Market size (NA, EU, Asia)	Estimated at USD 4–6 billion (2022)	IQVIA [3]

2.2. Treatment Landscape

Treatment Options	Description	Market Share (2022)	Notes
Preventive therapies	Beta-blockers, anticonvulsants, CGRP inhibitors	~30–40% of patients	Limited adherence and tolerability issues
Monoclonal antibody CGRP inhibitors	Erenumab, fremanezumab, galcanezumab	~60% of CGRP treatment segment	Injectable; high efficacy but limited patient preference for injections
Oral CGRP receptor antagonists	Atogepant, rimegepant (acute)	Emerging	Market share rapidly increasing due to convenience

2.3. Competitive Landscape

Competitor	Drug Name	Regulatory Status	Formulation	Key Differentiator
Eli Lilly	Rimegepant	FDA-approved (2020)	Oral (acute)	Approved for preventive use
Novartis	Fremanezumab	FDA-approved	Injection	Efficacy in both episodic and chronic migraine
Eli Lilly	Galcanezumab	FDA-approved	Injection	Pivotal in chronic migraine

Note: Atogepant’s differentiation lies in oral administration for preventive therapy, filling unmet patient preference.

---

3. Financial Trajectory: Sales Projections and Market Penetration

3.1. Adoption Assumptions

Parameter	Value	Notes
Initial Market Penetration (Year 1)	5–7%	Early adoption among migraine patients
Growth Rate (Year 2–5)	15–25% annually	Accelerated market penetration with expanding indications
Pricing per Dose	~$45–$55	Approximate wholesale acquisition cost (WAC) in the US
Total Addressable Market (TAM)	USD 4–6 billion	Based on current migraine prevalence

3.2. Revenue Forecast Scenarios (2022–2026)

Scenario	2022	2023	2024	2025	2026	Comments
Conservative	USD 200M	USD 300M	USD 500M	USD 700M	USD 900M	Slow adoption, high competition
Moderate	USD 250M	USD 450M	USD 750M	USD 1.1B	USD 1.4B	Above-average uptake
Optimistic	USD 300M	USD 550M	USD 900M	USD 1.3B	USD 1.7B	Rapid adoption, expanded indications

Note: Actual results dependent on market acceptance, insurance coverage, and competitive dynamics.

---

4. Regulatory and Commercial Factors Impacting Financial Outlook

Factor	Implication	Status
Label Expansion	Broadened indications to chronic migraine or other headache disorders	Under review or exploratory
Reimbursement Environment	Insurance reimbursement critical for prescribing rates	Positive coverage policies increase market penetration
Pricing Strategies	Tiered pricing, patient assistance programs	Influence access and sales volume
Patent Life and Exclusivity	Patent expiration not until mid/late 2030s	Market exclusivity lifetime supports revenue

---

5. Investment Considerations

Aspect	Details
Growth Potential	High, driven by patient preference for oral meds and expanding indications
Market Risks	Intense competition from injectable CGRP mAbs, potential pricing pressures, biosimilar entry
Regulatory Risks	Delays or restrictions on label expansion
Commercial Risks	Insurance coverage gaps, slow uptake due to physician or patient preferences
Strategic Opportunities	Combination therapy development, head-to-head trials, real-world evidence generation

---

6. Comparative Analysis with Similar Drugs

Parameter	Atogepant	Rimegepant	Galcanezumab	Erenumab
Approval Year	2021	2020	2018	2018
Indication	Episodic migraine preventive	Preventive and acute	Preventive	Preventive
Formulation	Oral	Oral	Injection	Injection
Market Penetration	Growing	Rapid	Mature	Mature

---

7. Strategic Competitive Positioning

• Strengths: First oral CGRP receptor antagonist for preventive migraine, high patient adherence potential.
• Weaknesses: Smaller market share compared to established injectable mAbs, limited long-term real-world data.
• Opportunities: Expanded indications, combination therapies, digital health integrations.
• Threats: Price competition, biosimilars or new entrants, market saturation.

---

8. Key Regulatory and Policy Influences

Regulatory Aspect	Impact	Details
FDA Approvals	Timeliness influences market entry	Approved in 2021; supplementary approvals ongoing
Reimbursement Policies	Crucial for uptake	US, EU, Japan policies favor oral over injectable medications
Pricing Regulations	Affects profitability	Price controls could pressure margins
Global Expansion	Expands TAM	Regulatory approvals underway in Europe, Japan, and emerging markets

---

9. FAQs

Q1: What is the competitive advantage of atogepant over existing migraine preventives?
Answer: Its oral formulation offers increased convenience and adherence relative to injectable CGRP monoclonal antibodies, which face limitations due to injection fatigue and needle aversion.

Q2: How does atogepant's market penetration compare to its competitors?
Answer: As a relatively new entrant, atogepant’s market share remains modest but is expected to grow rapidly with expanding indications and clinical adoption. Market share forecasts range from 5% initially to over 20% in 5 years.

Q3: What are the primary risks impacting the financial trajectory of atogepant?
Answer: Competition from existing mAbs, pricing pressures, insurance reimbursement hurdles, and potential regulatory delays.

Q4: How is the reimbursement environment affecting atogepant’s market growth?
Answer: Favorable reimbursement policies for oral medications boost adoption, though variability across healthcare systems may pose challenges.

Q5: What is the potential for global expansion of atogepant?
Answer: Significant, though contingent upon obtaining regulatory approvals in key markets like Europe, Japan, and emerging economies, which will increase the total addressable market substantially.

---

10. Key Takeaways

• Market Opportunity: The global migraine market is substantial (~USD 4–6 billion), with rising demand for oral preventive treatments.
• Competitive Edge: Atogepant’s oral route addresses patient preference and adherence issues relevant to the migraine population.
• Financial Outlook: Sales are projected to reach US$ 0.9–1.7 billion by 2026 under optimistic scenarios, with revenue growth driven by expanding indications and adoption.
• Risks and Challenges: Competition from established injectable mAbs, reimbursement variability, and market saturation pose risks.
• Strategic Recommendations: Continuous monitoring of regulatory developments, expanding indications, and real-world evidence generation are crucial for maximizing investment returns.

---

References

1. WHO. "Migraine Fact Sheet." World Health Organization, 2021.
2. IHS. "Headache Disorders—Epidemiology and Impact." International Headache Society, 2022.
3. IQVIA. "Global Migraine Market Report," 2022.

---

This analysis aims to inform strategic investment decisions regarding atogepant, emphasizing market opportunities, competitive positioning, financial projections, and risk factors.